carboplatin + etoposide

PreclinicalSmall molecule

carboplatin + etoposide is one of 93 small molecule programs targeting Neuroendocrine Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine CarcinomaActive, not recruiting

Small Cell Lung Cancer ( SCLC )Recruiting

MedulloblastomaActive, not recruiting

Neuroendocrine CarcinomaPhase 1/Phase 2

Active, not recruiting

Small Cell Lung Cancer ( SCLC )Preclinical

Recruiting

MedulloblastomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

96 competitors in Neuroendocrine Carcinoma

#DrugCompanyPhaseTrials

Tarlatamab-Dznl

Amgen

Phase 3

5 2

Tuoyi

CCoherus Oncology, Inc.

Phase 3

1 3

Inlyta

PPrism Pharmaceuticals

Phase 3

1 4

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

—5

Xpovio

KKaryopharm Therapeutics Inc

Sandostatin LAR

1 7

Keytruda

Merck & Co.

Phase 2

3 8

Tecentriq

Roche

Phase 2

2 9

Opdivo

Bristol-Myers Squibb

Phase 2

2 10

Yervoy

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

Small Cell Lung Cancer ( SCLC )

NCT05652686

Clinical

Trials by Indication[1]

Phase II1 trial

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Unknown status·HHaihe Biopharma Co., Ltd.·Phase 2/3·NCT04254471·313 enrolled

Medulloblastoma1 trial

Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1/2·NCT02025881·29 enrolled

Advanced Solid Tumors1 trial

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT02658214·32 enrolled

Small Cell Lung Cancer ( SCLC )1 trial

An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)

Recruiting·PPhanes Therapeutics·Preclinical·NCT05652686·203 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for carboplatin + etoposide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — carboplatin + etoposide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for carboplatin + etoposide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AstraZeneca

carboplatin + etoposide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Phase II1 trial

Medulloblastoma1 trial

Advanced Solid Tumors1 trial

Small Cell Lung Cancer ( SCLC )1 trial

References

Drug Info

Quick Facts

Related News